ERBB2 and urinary bladder carcinoma: To determine the impact of lovastatin-mediated CAV1 depletion on trastuzumab’s binding to HER2-positive tumors, a pilot study was performed using separate bilateral xenografts of UMUC14 bladder cancer and NCIN87 gastric cancer (Supplementary Fig. 6).